Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I mass balance study of radiolabeled R924548 in healthy men
NL-OMON37118Phase 1Active, not recruiting
- Sponsor
- Rigel Pharmaceuticals, Inc.
- Start
- Jun 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of R548 in autoimmune inflammatory diseases and rheumatoid arthritis (RA), sponsored by Rigel Pharmaceuticals, Inc. Primary endpoints: Plasma pharmacokinetics of metabolites, Total radioactivity in plasma and whole blood and 2 more. Started Jun 2012; status: active, not recruiting.
02
Drugs
R548
03
Conditions
autoimmune inflammatory diseasesrheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON37118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37118.